Current threats on gene doping - a systematic review

1. Barton-Davis E.R., Shoturma D.I., Musaro A., Rosenthal N., Sweeney H.L. (1998). Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function, Proc. Natl. Acad. Sci. USA, 95:15603–15607,10.1073/pnas.95.26.15603Search in Google Scholar

2. McPherron A.C., Lawler A.M., Lee S.J. (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member, Nature, 387, 83–90.10.1038/387083a0Search in Google Scholar

3. https://www.scientificamerican.com/article/olympics-genedoping-expert/, accessed on 20th of September, 2018.Search in Google Scholar

4. https://www.wada_ama.org/sites/default/files/prohibited_l ist_2018_en.pdf, accessed on 20th of September, 2018.Search in Google Scholar

5. https://annualmeeting.asgct.org/about_gene_therapy/diseases.php, accessed on 24th of September, 2018.Search in Google Scholar

6. MacLaren, R.E. et al. (2014) Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial, The Lancet, 383(9923), 1129-1137.10.1016/S0140-6736(13)62117-0Search in Google Scholar

7. Petrs-Silva H., Linden R. (2014). Advances in gene therapy technologies to treat retinitis pigmentosa, Clinical Opthalmology, 8, 127-136.10.2147/OPTH.S38041Search in Google Scholar

8. Nathwani A.C. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B, The New England Journal of Medicine, 365(25), 2357-2365.Search in Google Scholar

9. Nienhuis A.W. (2013). Development of gene therapy for blood disorders: an update, Blood 122(9), 1556-1564.10.1182/blood-2013-04-453209Search in Google Scholar

10. Wells D.J. (2008). Gene doping: the hype and the reality, Br J Pharmacol. Jun, 154(3), 623-631.10.1038/bjp.2008.144Search in Google Scholar

11. http://am.e_nformation.ro/login?url=http://www.webofkno wledge.com, accessed on 25th of September, 2018.Search in Google Scholar

12. https://www.wada-ama.org/en/gene-doping, accessed on 12th of September, 2018.Search in Google Scholar

13. https://www.wada_ama.org/sites/default/files/prohibited_l ist_2018_summary_of_modifications_en.pdf, accessed on 12th of September, 2018.Search in Google Scholar

14. Lunde G.I., Ekmark M., Rana Z.A., Buonanno A., Gundersen K. (2007). PPARδ expression is influenced by muscle activity and induces slow muscle properties in adult rat muscles after somatic gene transfer, J Physiol., 582(3),1277–1287.10.1113/jphysiol.2007.133025Search in Google Scholar

15. Wang Y.X., Zhang C.L, Yu R.T., Cho H.K., Nelson M.C., Bayuga-Ocampo C.R., Ham J., Kang H., Evans R.M. (2004). Regulation of muscle fiber type and running endurance by PPARdelta, PLoS Biol., Oct., 2(10): e294.10.1371/journal.pbio.0020294Search in Google Scholar

16. Lee C.H., Olson P., Hevener A., Mehl I., Chong L.W., Olefsky J.M., Gonzalez F.J., Ham J., Kang H., Peters J.M., Evans R.M.(2006). PPARδ regulates glucose metabolism and insulin sensitivity, Proc. Natl. Acad. Sci., 103, 3444–3449.10.1073/pnas.0511253103Search in Google Scholar

17. Brzeziańska E., Domańska D., & Jegier A. (2014). Gene doping in sport–perspectives and risks, Biology of sport, 31(4), 251-259.10.5604/20831862.1120931Search in Google Scholar

18. Shyu K.G., Chang H., Wang B.W., Kuan P. (2003). Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia, Am. J. Med., 1, 85–92.10.1016/S0002-9343(02)01392-XSearch in Google Scholar

19. Lippi G., Guidi G.C. (2004). Gene manipulation and improvement of athletic performances: new strategies in blood doping, Br. J. Sports Med., 38: 641.10.1136/bjsm.2004.013623Search in Google Scholar

20. Winder W.W., Hardie D.G. (1999). AMP–activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes, Am. J. Physiol., 277: E1–E10.10.1152/ajpendo.1999.277.1.E1Search in Google Scholar

21. Rantzau C., Christopher M., Alford F.P. (2008). Contrasting effects of exercise, AICAR, and increased fatty acid supply on in vivo and skeletal muscle glucose metabolism, J. Appl. Physiol.,104, 363–370.10.1152/japplphysiol.00500.2007Search in Google Scholar

22. Narkar V.A., Downes M., Yu R.T., Embler E., Wang Y.X., Banayo E., Mihaylova M.M., Nelson M.C., Zou Y., Juguilon H., Kang H., Shaw R.J., Evans R.M. (2008). AMPK and PPARd agonists are exercise mimetics, Cell, 134, 405–415.10.1016/j.cell.2008.06.051Search in Google Scholar

23. Lee S., Barton E.R., Sweeney H.L., Farrar R.P. (2004). Viral expression of insulin–like growth factor–I enhances muscle hypertrophy in resistance–trained rats, J. Appl. Physiol., 96, 1097–1104.10.1152/japplphysiol.00479.2003Search in Google Scholar

24. Doessing S., Kjaer M. (2005). Growth hormone and connective tissue in exercise, Scand. J. Med. Sci. Sports,15, 202–210.10.1111/j.1600-0838.2005.00455.xSearch in Google Scholar

25. Whittemore L.A. et al. (2003). Inhibition of myostatin in adult mice increases skeletal muscle mass and strength, Biochem. Biophys. Res. Commun., 24, 965–971.10.1016/S0006-291X(02)02953-4Search in Google Scholar

26. Hakimi P., Yang J., Casadesus G., Massillon D., Tolentino-Silva F., Nye C.K., Cabrera M.E., Hagen D.R., Utter C.B., Baghdy Y., Johnson D.H., Wilson D.L., Kirwan J.P., Kalhan S.C., Hanson R.W. (2007). Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse, J. Biol. Chem., 9, 32844–32855.10.1074/jbc.M706127200Search in Google Scholar

27. Beale E., Forest C., Harvey B.J. (2007). PCK1 and PCK2 as candidate diabetes and obesity genes, Cell Biochemistry and Biophysics, 48(2-3), 89-95.10.1007/s12013-007-0025-6Search in Google Scholar

28. Wilson S.P., Yeomans D.C., Bender M.A., Lu Y., Goins W.F., Glorioso J.C. (1999). Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus, Proc. Natl. Acad. Sci. USA, 96, 3211–3216.10.1073/pnas.96.6.3211Search in Google Scholar

29. Machelska H. et al. (2009). Peripheral non-viral MIDGE vector-driven delivery of beta-endorphin in inflammatory pain, Mol, Pain. 14(5), 72.10.1186/1744-8069-5-72Search in Google Scholar

30. Hao S., Wolfe D., Glorioso J.C., Mata M., Fink D.J. (2009). Effects of transgene-mediated endomorphin-2 in inflammatory pain, Eur. J. Pain, 13, 380–386.10.1016/j.ejpain.2008.05.008Search in Google Scholar

31. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., Wilson J.M., Batshaw M.L. (2003). Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol. Genet. Metab., 80(1-2), 148-58.10.1016/j.ymgme.2003.08.016Search in Google Scholar

32. Perry J.K., Starling Emerald B., Mertani H.C., Lobie P.E. (2006). The oncogenic potential of growth hormone, Growth Hormone & IGF Research, 16(5–6), 277-289;10.1016/j.ghir.2006.09.006Search in Google Scholar

33. Anderson L., Tamayose J.M., Garcia J.M. (2018). Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects, Molecular and Cellular Endocrinology, 464 (C), 65-74.10.1016/j.mce.2017.06.010Search in Google Scholar

34. Bergestrom J. (1993). New aspects of erythropoietin treatment, J. Int. Med., 233,1–18.10.1111/j.1365-2796.1993.tb00998.xSearch in Google Scholar

35. Gao G., Lebherz C., Weiner D. J., Grant R., Calcedo et al. (2004). Erythropoietin gene therapy leads to autoimmune anemia in macaques, Blood, 103(9), 3300-3302.10.1182/blood-2003-11-3852Search in Google Scholar

36. Chenuaud P., Larcher T., Rabinowitz J. E., Provost N., Cherel Y., Casadevall N., Samulski R.J., Moullier P. (2004). Autoimmune anemia in macaques following erythropoietin gene therapy, Blood, 103(9), 3303-3304.10.1182/blood-2003-11-3845Search in Google Scholar

37. Horgan J. (2016). Could Olympians Be Tweaking Their Genes?, https://blogs.scientificamerican.com/cross-check/couldolympians-be-tweaking-their-genes/ accessed on 17th of September, 2018.Search in Google Scholar

38. Thevis M., Geyer H., Thomas A., Schanzer W. (2011). Trafficking of drug candidates relevant for sports drug testing: Detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet, Drug Testing and Analysis, 3 (5), 331-336.10.1002/dta.283Search in Google Scholar

39. Fischetto G., Bermon S. (2013). From Gene Engineering to Gene Modulation and Manipulation: Can We Prevent or Detect Gene Doping in Sports?, Sports Medicine, 43(10), 965-977.10.1007/s40279-013-0075-4Search in Google Scholar

40. Friedmann T. (2013). Genetic and cellular approaches to doping and doping detection, WADA Symposium on Gene and Cell Doping, Beijing, retrieved from https://www.wadaama.org/sites/default/files/resources, on12th of September, 2018.Search in Google Scholar

41. Baoutina A., Bhat S., Zheng M., Partis L., Dobeson M., Alexander I.E., Emslie K.R. (2016). Synthetic certified DNA reference material for analysis of human erythropoietin transgene and transcript in gene doping and gene therapy, Gene therapy 23(10), 708-717.10.1038/gt.2016.47Search in Google Scholar

42. Mullin E. (2018). 2017 Was the Year of Gene-Therapy Breakthroughs, accessed on 27th of October, 2018 https://www.technologyreview.com/s/609643/2017-wasthe-year-of-gene-therapy-breakthroughs/.Search in Google Scholar

43. Hall S. (2018). Olympic gene doping: How WADA is managing new performance-enhancing technologies, accessed from https://geneticliteracyproject.org/2018/02/13/ on 10th of October, 2018.Search in Google Scholar

44. Rankinen T., Perusse L., Rauramaa R., Rivera M.A., Wolfarth B., Bouchard C. (2004). The human gene map for performance and health-related fitness phenotypes: the 2003 update, Med. Sci. Sports Exerc., 36, 1451 – 1469.10.1249/01.MSS.0000139902.42385.5FSearch in Google Scholar

45. Wenner M. (2008). How to Be Popular duringthe Olympics: Be H. Lee Sweeney, Gne Dopin Expert, Scientific America, August 15, https://www.scientificamerican.com/article/olympicsgene-doping-expert/ on 12th of September, 2018.Search in Google Scholar